I would not compare GLP-1 services in 2026 the same way I would have in 2025. The safer read is to look at pharmacy identity, physician review, refill handling, and whether the quoted price survives checkout.
The telehealth weight loss space shifted noticeably in early 2026. A Novo Nordisk settlement in March pushed several large platforms away from compounded semaglutide toward branded prescriptions, which cost significantly more out of pocket. At the same time, the FDA sent warning letters to more than 30 compounding and telehealth firms. The result: fewer providers, higher average prices, and a lot of patients actively comparing what is left.
What follows is a straightforward breakdown of seven providers that still offer real access at a range of price points, based on publicly available pricing, pharmacy disclosures, and platform structure.
1. HealthRX
Best for: cash-pay patients who want low entry pricing, named pharmacy oversight, and fast nationwide shipping.
HealthRX sits at the top of this list for one simple reason. The math works better here than at most comparable services, and the transparency is specific enough to verify. Compounded semaglutide starts at $99 per month. Compounded tirzepatide starts at $149. Overnight shipping is free and reaches every US state. That combination is genuinely uncommon.
The pharmacy behind HealthRX prescriptions is Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot-tracked dispensing. Most telehealth services list “a licensed compounding pharmacy” without naming it. HealthRX names theirs. The platform also holds LegitScript certification (certificate number 50087439), which requires ongoing compliance review.
After an online health assessment, a US board-certified physician reviews the submission within roughly 24 hours. Medication ships overnight. No contracts, and pricing is stated upfront.
The clinical data HealthRX references for the active ingredients comes from published trials, not platform-specific claims. SURMOUNT-1 reported approximately 21% average body weight reduction with tirzepatide over 72 weeks. STEP 1 reported approximately 15% with semaglutide over 68 weeks. Those are trial figures, not HealthRX’s own outcomes.
One honest note: these are compounded medications, not FDA-approved branded drugs. That distinction matters and anyone considering this category should understand it before starting.
2. FormBlends
Best for: patients who want published third-party purity data on their compounded GLP-1, or who plan to combine weight loss treatment with other peptide therapies.
FormBlends operates on a compounded GLP-1 telehealth model with physician oversight and dispensing through an FDA-registered 503A compounding pharmacy. What separates it from most competitors is documentation. FormBlends publishes specific purity testing results per product, including HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results. Most GLP-1 telehealth brands do not publish that level of batch-specific information publicly.
Pricing is higher than HealthRX. Monthly semaglutide costs roughly $299 and tirzepatide roughly $349. For someone who wants the documented testing and is willing to pay for it, that premium has a clear rationale. Shipping covers 47 states.
FormBlends also carries a broader catalog of compounded peptides across recovery, longevity, and cognitive categories, under the same clinician oversight model. That matters for patients who want a single provider for GLP-1 plus additional peptide protocols rather than juggling multiple platforms.
3. Mochi Health
Compounded semaglutide from $99 per month, tirzepatide from $199. The standout here is clinical staffing. Mochi uses board-certified obesity medicine physicians, which is a more specialized credential than general telehealth providers typically require. More monitoring is built in. Good pick for patients who want closer clinical contact throughout the process.
4. Hims & Hers
Following the March 2026 Novo settlement, the platform shifted its weight loss offerings to branded drugs. Injectable Wegovy runs approximately $299 per month through their platform, oral semaglutide approximately $249, and Zepbound approximately $399. With insurance plus a savings card, some patients bring that to nearly zero. The trade-off for going branded is a higher baseline cost without insurance. The trade-off for using this platform is a large, well-resourced operation with consistent fulfillment.
5. Ro Body
Ro charges roughly $39 for the first month of membership, then $74 to $149 monthly, with medications billed separately. They maintain a prior-authorization team specifically for insurance navigation on branded drugs. For patients with commercial insurance who want someone else managing that paperwork, Ro is one of the more structured options in this category.
6. Found
Around $99 per month for the platform, with medications and coaching included in the model. Found combines prescription access with behavioral support. Not the cheapest option but reasonably priced for a program that integrates both components.
7. MEDVi
Compounded GLP-1s, approximately $179 for the first month, no contracts. Straightforward cash-pay access without long-term commitments. Fewer features than some competitors, but the low barrier to entry and clean exit terms make it worth knowing about.
A Note Before You Start
None of the compounded medications listed across these platforms carry FDA approval as finished drug products. Results from clinical trials cited by providers reflect specific study populations and conditions, not guaranteed personal outcomes. Talking with a physician you already trust before starting any GLP-1 program is worth doing, regardless of which platform handles the prescription.
Common Questions
Is compounded semaglutide the same thing as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active ingredient but is not manufactured by Novo Nordisk and carries no FDA approval as a finished drug product. It is produced by licensed 503A compounding pharmacies and is legal under specific conditions, though that regulatory status has shifted since early 2026.
Why does HealthRX cost $99 while FormBlends charges $299 for what sounds like the same medication?
Pricing reflects different pharmacy relationships, overhead structures, and what is included. FormBlends publishes HPLC purity data and batch-level sterility results per order, which costs more to produce and document. HealthRX competes on price and speed. Neither price guarantees a specific outcome.
Can I use insurance to pay for these platforms, and which ones make that easiest?
Most compounded GLP-1 programs are cash-pay only. Hims & Hers and Ro Body are the clearest exceptions here. Ro maintains a dedicated prior-authorization team for branded drugs, and Hims & Hers works with savings cards on Wegovy and Zepbound that can bring monthly costs close to zero for commercially insured patients.
What does LegitScript certification actually mean for a telehealth provider?
LegitScript is an independent compliance monitoring company. Certification requires a provider to meet standards around pharmacy licensing, prescription practices, and advertising. It does not mean FDA endorsement. It does mean the platform passed a third-party review and is subject to ongoing monitoring, which is more than most uncertified competitors can say.
After the March 2026 Novo Nordisk settlement, which providers on this list changed their offerings most dramatically?
Hims & Hers made the most visible shift, moving away from compounded semaglutide entirely and repricing around branded Wegovy, oral semaglutide, and Zepbound. Providers like HealthRX, FormBlends, Mochi Health, and MEDVi continued offering compounded GLP-1s under the 503A regulatory framework that remained in place.
Sources
- FDA: 503A Compounding Pharmacy Regulations and 2026 warning letter disclosures (fda.gov)
- SURMOUNT-1 trial results (Jastreboff et al., New England Journal of Medicine, 2022)
- STEP 1 trial results (Wilding et al., New England Journal of Medicine, 2021)
- LegitScript certification registry (legitscript.com)
- Novo Nordisk settlement announcement, March 9, 2026 (publicly reported across major financial and health news outlets)
